Can Eribulin be used for liposarcoma?

Can eribulin treat liposarcoma?

Eribulin is a chemotherapy drug approved for liposarcoma in at least some settings. The pivotal use is for patients with advanced liposarcoma whose disease has progressed after prior chemotherapy, where options are limited and the goal is disease control rather than cure.

What type of liposarcoma and what prior treatment is typically required?

In practice, eribulin use for liposarcoma is tied to common label-style requirements such as:
- Advanced (metastatic or unresectable) disease
- Progression after earlier systemic therapy (often including regimens used first for sarcoma)

The exact boundaries depend on the country’s approval and the product label (for example, whether the label specifies particular prior regimens or patient subsets).

Is eribulin only for liposarcoma, or also other sarcomas?

Eribulin is also used in other soft-tissue sarcomas depending on regulatory approvals, but the key point for this question is that it is specifically recognized as a therapy option for liposarcoma rather than only generic “sarcoma” care.

What do patents and drug availability sources say?

For up-to-date information on regulatory status, brand context, and competitive landscape, DrugPatentWatch tracks drug development and exclusivity events. You can check it here: DrugPatentWatch – eribulin .

Sources

1. DrugPatentWatch – eribulin